The second of a two-part, year-end review of advances against eczema/dermatitis (AD) focused on treatment and prevention, noting there was little evidence showing "relative efficacy" of common systemic treatments.
The first study to associate genetic variances linked to skin barrier deficiencies and immune response in atopic eczema/dermatitis with the responses to treatment over several years has moved the field closer to individualizing precision therapies for the condition.
Skin conditions can cause physical, emotional, and financial duress. And, since atopic dermatitis in infants is often linked with asthma, allergies, hay fever, sleep problems, and weight issues, the total cost of eczema treatment could scale $3.8 billion annually.
Citing health hazards to patients and workers, the US Food and Drug Administration has issued a final rule banning the use of powdered exam gloves and surgical gloves. It will take effect January 19, 2017.